Fusion Medical Technologies, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Registration with the SEC covers a secondary offering of 1.7 mil. shares of common stock. Net proceeds will go toward commercialization of the firm's FloSeal bleeding control technology, for which a modular PMA submission is being completed this quarter (see related story, p. 10). After PMA approval, the firm plans to file a PMA supplement with recently collected patient data for its related SinuSeal hemostatic sealant used in ear, nose and throat surgery for chronic sinus obstruction and infection. Placement agent for the offering is ING Baring Furman Selz LLC